Dr. John Cush RheumNow
3 years 3 months ago
View an interactive disease modification patient journey from the #LupusEducatorsNetwork and learn about the importance of helping to prevent renal damage in your patients with #LupusNephritis. #SponsoredbyGSKUSMA
https://t.co/XKG25eVSfa https://t.co/Jbo2iR6OuJ
Dr. John Cush RheumNow
3 years 3 months ago
2010 Colchicine Price Hikes Adversely Affected Gout Care
Research shows that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use,.
https://t.co/WS721SlM6p https://t.co/BBdqDVGolq
Dr. John Cush RheumNow
3 years 3 months ago
Orphan drugs target rare dz <200k. New drugs (2008-2016) compared 5 yr sales 86 orphan Rx to 232 non-orphan = similar sales- Orphan ($719 mill) vs nonorphan ($812 mill). But orphan Rx lower volume offset by higher prices (7X higher) than nonorphan drugs https://t.co/I8kb4A0eyG https://t.co/gEQpssRVkg
Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients. The use of newer b/tsDMARD was hampered by limited efficacy and durability.
This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!
Dr. John Cush RheumNow
3 years 3 months ago
May 16th--Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances
This webinar will feature highlights from these lectures followed by live audience Q & A:
-New Therapies for PMR & GCA
-Assessment of GCA and PMR
-GPA Treatment Choices
https://t.co/fphj3seU3K https://t.co/GSL41UZZ2Y
Dr. John Cush RheumNow
3 years 3 months ago
Pregnancy in PsA
RheumNow Live 2023: Christina Chambers, PhD, MPH, University of California, San Diego School of Medicine
https://t.co/ImgAwCvawE https://t.co/9GCZ1tBmkV
Dr. John Cush RheumNow
3 years 3 months ago
Study of 6039 NHL hockey players showed mortality rates were similar between fighters & controls (3.9% v4.2%) & Penalized vs not (7.1.% v 5.5%). Yet controls lived (~56yrs) avg of 10 yrs longer than fighters/penalized (~46yrs) w/ more suicide & overdose https://t.co/EKOeEKSejN https://t.co/7Axpz0QibY
Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised. A EULAR task force has established recommendations for screening and prophylaxis against OI.
Dr. John Cush RheumNow
3 years 3 months ago
JAK inhibitors in Psoriasis and PsA
RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine
https://t.co/OV4rRR6eCh https://t.co/uY9MnwGveV
Dr. John Cush RheumNow
3 years 3 months ago
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported.
https://t.co/SPmdBJ8IFh https://t.co/ad2j6XaSkK
Dr. John Cush RheumNow
3 years 3 months ago
Did you miss Tuesday Night Rheumatology this week?
This webinar features highlights from:
Preclinical RA – To Treat or Not To Treat
Year of the JAKi
Fibroblast/Stromal Cells
https://t.co/yVQLtG6fEe https://t.co/WMXcKdqwdP
A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).
